Premium
Bevacizumab beyond disease progression for advanced non–small cell lung cancer: Does persistence have its rewards?
Author(s) -
GuijarroMuñoz Irene,
Roarty Emily B.,
Heymach John V.
Publication year - 2016
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.29894
Subject(s) - bevacizumab , medicine , persistence (discontinuity) , chemotherapy , vascular endothelial growth factor , lung cancer , oncology , blockade , disease , vegf receptors , receptor , geotechnical engineering , engineering
Persistence pays off when it comes to the vascular endothelial growth factor inhibitor bevacizumab in non–small cell lung cancer patients who have progressed on first‐line chemotherapy. Continued vascular endothelial growth factor blockade after progression on first‐line therapy may provide at least a modest benefit when it is continued with second‐line chemotherapy. See also pages 000–000